Literature DB >> 26298567

Antihypertensive Therapies and Cognitive Function: a Review.

Nisharahmed Kherada1, Todd Heimowitz, Clive Rosendorff.   

Abstract

Increasing life expectancy has made old age-related health problems like dementia and cognitive decline more prevalent, and these are rapidly becoming important causes of disability and poor quality of life, causing significant add-ons to health-care costs worldwide. Hypertension is the most important modifiable vascular risk factor for the development and progression of both cognitive decline and dementia. In many observational and randomized studies, antihypertensive therapies have been shown to be beneficial in slowing cognitive decline. However, due to observed discrepancies by these studies, there is a lack of consensus on the best antihypertensive strategy for the prevention or slowing of cognitive decline. It is also not clear whether the beneficial effect of antihypertensive therapy is due to the use of a specific class of agents or combination therapy. Thus, we present a comprehensive review of overall antihypertensive therapies and cognition and of the individual antihypertensive therapy classes with their specific protective mechanisms and available clinical evidence behind their effect on cognitive function.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26298567     DOI: 10.1007/s11906-015-0592-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  70 in total

1.  Midlife blood pressure and dementia: the Honolulu-Asia aging study.

Authors:  L J Launer; G W Ross; H Petrovitch; K Masaki; D Foley; L R White; R J Havlik
Journal:  Neurobiol Aging       Date:  2000 Jan-Feb       Impact factor: 4.673

2.  The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia.

Authors:  L Pantoni; C Bianchi; M Beneke; D Inzitari; A Wallin; T Erkinjuntti
Journal:  J Neurol Sci       Date:  2000-04-15       Impact factor: 3.181

3.  Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial.

Authors:  M Di Bari; M Pahor; L V Franse; R I Shorr; J Y Wan; L Ferrucci; G W Somes; W B Applegate
Journal:  Am J Epidemiol       Date:  2001-01-01       Impact factor: 4.897

4.  Carvedilol as a potential novel agent for the treatment of Alzheimer's disease.

Authors:  Jun Wang; Kenjiro Ono; Dara L Dickstein; Isabel Arrieta-Cruz; Wei Zhao; Xianjuan Qian; Ashley Lamparello; Rakesh Subnani; Mario Ferruzzi; Constantine Pavlides; Lap Ho; Patrick R Hof; David B Teplow; Giulio M Pasinetti
Journal:  Neurobiol Aging       Date:  2010-07-01       Impact factor: 4.673

5.  15-year longitudinal study of blood pressure and dementia.

Authors:  I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg
Journal:  Lancet       Date:  1996-04-27       Impact factor: 79.321

6.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.

Authors:  Françoise Forette; Marie-Laure Seux; Jan A Staessen; Lutgarde Thijs; Marija-Ruta Babarskiene; Speranta Babeanu; Alfredo Bossini; Robert Fagard; Blas Gil-Extremera; Tovio Laks; Zhanna Kobalava; Cinzia Sarti; Jaakko Tuomilehto; Hannu Vanhanen; John Webster; Yair Yodfat; Willem H Birkenhäger
Journal:  Arch Intern Med       Date:  2002-10-14

7.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

8.  Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study.

Authors:  Rebecca P Gelber; G Webster Ross; Helen Petrovitch; Kamal H Masaki; Lenore J Launer; Lon R White
Journal:  Neurology       Date:  2013-08-02       Impact factor: 9.910

9.  Long-term effects of secondary prevention on cognitive function in stroke patients.

Authors:  Abdel Douiri; Christopher McKevitt; Eva S Emmett; Anthony G Rudd; Charles D A Wolfe
Journal:  Circulation       Date:  2013-08-09       Impact factor: 29.690

Review 10.  Brain renin angiotensin in disease.

Authors:  M Ian Phillips; Edilamar Menezes de Oliveira
Journal:  J Mol Med (Berl)       Date:  2008-04-02       Impact factor: 4.599

View more
  9 in total

Review 1.  Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.

Authors:  Romain Barus; Johana Béné; Julie Deguil; Sophie Gautier; Régis Bordet
Journal:  Br J Pharmacol       Date:  2019-03-31       Impact factor: 8.739

Review 2.  Use of Biomarkers in the Evaluation and Treatment of Hypertensive Patients.

Authors:  Gemma Currie; Christian Delles
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

3.  Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study.

Authors:  Jackie Bosch; Martin O'Donnell; Balakumar Swaminathan; Eva Marie Lonn; Mikul Sharma; Gilles Dagenais; Rafael Diaz; Kamlesh Khunti; Basil S Lewis; Alvaro Avezum; Claes Held; Matyas Keltai; Christopher Reid; William D Toff; Antonio Dans; Lawrence A Leiter; Karen Sliwa; Shun Fu Lee; Janice M Pogue; Robert Hart; Salim Yusuf
Journal:  Neurology       Date:  2019-02-27       Impact factor: 9.910

4.  Relationships between residual blood pressure variability and cognitive function in the general population of the PAMELA study.

Authors:  Marijana Tadic; Cesare Cuspidi; Michele Bombelli; Rita Facchetti; Giuseppe Mancia; Guido Grassi
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-11-14       Impact factor: 3.738

Review 5.  Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden.

Authors:  Marijana Tadic; Cesare Cuspidi; Dagmara Hering
Journal:  BMC Cardiovasc Disord       Date:  2016-11-03       Impact factor: 2.298

6.  A cross-sectional study to evaluate metabolic and demographic factors affecting cognitive function among low educated internal medicine outpatients.

Authors:  Feride Alakus; Serife A Helvaci; Mustafa Temizel; Yucel Arman
Journal:  Neurosciences (Riyadh)       Date:  2017-01       Impact factor: 0.906

Review 7.  Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits.

Authors:  Mirella Russo; Matteo A De Rosa; Dario Calisi; Stefano Consoli; Giacomo Evangelista; Fedele Dono; Matteo Santilli; Alberto Granzotto; Marco Onofrj; Stefano L Sensi
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

8.  Correlation study of Framingham risk score and vascular dementia: An observational study.

Authors:  Shan-Shan Li; Jie Zheng; Bin Mei; Han-Yao Wang; Miao Zheng; Kai Zheng
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease.

Authors:  Ziheng Hu; Lirong Wang; Shifan Ma; Levent Kirisci; Zhiwei Feng; Ying Xue; William E Klunk; M Ilyas Kamboh; Robert A Sweet; James Becker; Qianzhou Lv; Oscar L Lopez; Xiang-Qun Xie
Journal:  Alzheimers Dement (N Y)       Date:  2018-10-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.